• Explore /
  • Poster
  • / UPGRADE-A: Phase 1 expansion trial of the NaPi2b-directed antibody drug conjugate (ADC) upifitamab rilsodotin (UpRi) in combination with carboplatin in patients with high-grade serous ovarian cancer (HGSOC).

UPGRADE-A: Phase 1 expansion trial of the NaPi2b-directed antibody drug conjugate (ADC) upifitamab rilsodotin (UpRi) in combination with carboplatin in patients with high-grade serous ovarian cancer (HGSOC).

Abstract Poster

Authors

null

John L. Hays

Wexner Medical Center and The James Cancer Hospital, Ohio State University, Columbus, OH

John L. Hays , Claire Frances Friedman , Nehal Lakhani , Charles K Anderson , Joseph Buscema , Linda R. Duska , Erika P. Hamilton , Sarah E. Taylor , Cassandra Carrington , Robert Allen Burger , Theresa Louise Werner

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2023 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Gynecologic Cancer

Track

Gynecologic Cancer

Sub Track

Ovarian Cancer

Clinical Trial Registration Number

NCT04907968

Citation

J Clin Oncol 41, 2023 (suppl 16; abstr TPS5613)

DOI

10.1200/JCO.2023.41.16_suppl.TPS5613

Abstract #

TPS5613

Poster Bd #

307b

Abstract Disclosures

Similar Posters

First Author: Hans Gelderblom

First Author: Erika P. Hamilton

First Author: Adam M. Sonabend

First Author: Alexander I. Spira